Blue®M Gel Versus Hyaluronic Acid for Stability of Immediately Loaded Dental Implants

September 21, 2026 updated by: Fahad awad, Mansoura University

Topical Oxygen Therapy (Blue®M Gel) Versus Hyaluronic Acid on the Stability of Immediately Loaded Dental Implants in the Posterior Maxilla

This randomized controlled clinical trial aims to compare the effect of topical oxygen therapy (Blue®M Gel) and hyaluronic acid on the stability of immediately loaded dental implants placed in the posterior maxilla. Twenty-four dental implants will be placed in eligible patients and randomly assigned to one of three groups: control implants without surface treatment, implants immersed in Blue®M Gel before placement, and implants immersed in hyaluronic acid gel before placement.

Implant stability will be evaluated using resonance frequency analysis immediately after implant placement and during follow-up. Clinical healing outcomes, including pain, edema, soft tissue inflammation, wound dehiscence, and signs of infection, will also be assessed. Radiographic evaluation of crestal bone level changes will be performed using cone beam computed tomography (CBCT). The study seeks to determine whether topical oxygen therapy or hyaluronic acid can improve implant stability and peri-implant healing in the posterior maxilla.

Study Overview

Detailed Description

Dental implants are a predictable treatment option for the replacement of missing teeth. However, implant placement in the posterior maxilla remains challenging because of reduced bone density, sinus pneumatization, and limited residual bone volume. Achieving adequate primary stability is particularly important when immediate loading protocols are used.

Blue®M Gel is an oxygen-releasing topical gel that provides controlled delivery of active oxygen and contains lactoferrin, which may support wound healing, reduce bacterial load, and enhance tissue regeneration. Hyaluronic acid is a naturally occurring glycosaminoglycan that plays an important role in tissue repair, modulation of inflammation, and bone regeneration. Both materials have demonstrated beneficial effects on soft and hard tissue healing.

This study will be conducted as a randomized controlled clinical trial including patients requiring replacement of one or more missing teeth in the posterior maxilla. A total of 24 implants will be inserted and randomly allocated into three equal groups:

Group I: Immediate loaded implants without surface treatment (control group).

Group II: Immediate loaded implants immersed in Blue®M Gel before placement.

Group III: Immediate loaded implants immersed in hyaluronic acid gel before placement.

All implants will be placed using a standardized surgical protocol. Implant stability will be measured immediately after placement and at follow-up intervals using resonance frequency analysis and Implant Stability Quotient (ISQ) values. Clinical healing parameters will be evaluated postoperatively, including pain, edema, soft tissue inflammation, wound dehiscence, and signs of infection. Radiographic assessment of crestal bone level changes will be performed using CBCT imaging.

The primary objective of the study is to compare the effect of topical oxygen therapy and hyaluronic acid on implant stability in immediately loaded dental implants placed in the posterior maxilla. Secondary objectives include evaluation of peri-implant soft tissue healing and radiographic bone changes during the follow-up period.

Study Type

Interventional

Enrollment (Estimated)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients aged 18-45 years.
  2. Patients with one or more missing teeth in the posterior maxilla.
  3. Adequate bone volume (width ≥ 6 mm and height ≥ 12 mm from maxillary sinus floor).
  4. Good oral hygiene and motivation for oral rehabilitation.

Exclusion Criteria:

  1. Patients with systemic or local diseases contraindicating implant surgery.
  2. Smokers.
  3. History of radiotherapy or chemotherapy.
  4. Pregnant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control Group

Patients will receive immediately loaded dental implants without any surface conditioning or immersion in adjunctive agents prior to placement in the posterior maxilla

Experimental: Blue®M Gel Group

Patients will receive immediately loaded dental implants immersed in topical oxygen therapy gel (Blue®M Gel) prior to placement in the posterior maxilla

Topical oxygen-releasing gel used for implant surface conditioning prior to placement to enhance healing and implant stability.

Experimental: Hyaluronic Acid Group

Patients will receive immediately loaded dental implants immersed in hyaluronic acid gel prior to placement in the posterior maxilla.

Viscoelastic gel used for implant surface immersion prior to placement to enhance soft and hard tissue healing and improve implant stability.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implant Stability Quotient (ISQ)
Time Frame: Immediately after implant placement and follow up visits during the 6 months

Primary implant stability will be measured using Resonance Frequency Analysis (RFA) and expressed as Implant Stability Quotient (ISQ) values.

Immediately after implant placement and follow up visits during the 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Marginal (crestal) bone level changes around the dental implants
Time Frame: 6 months

assessed radiographically using standardized periapical radiographs during the 6-month follow-up period.

6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Fahad A Alqahtani, Faculty of Dentistry, Mansoura University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 12, 2026

Primary Completion (Estimated)

February 12, 2027

Study Completion (Estimated)

March 12, 2027

Study Registration Dates

First Submitted

September 10, 2026

First Submitted That Met QC Criteria

September 21, 2026

First Posted (Actual)

September 28, 2026

Study Record Updates

Last Update Posted (Actual)

September 28, 2026

Last Update Submitted That Met QC Criteria

September 21, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be shared due to ethical and confidentiality considerations. The dataset contains sensitive clinical and radiographic information related to dental implant patients, and sharing may compromise patient privacy. Additionally, no plan for external data sharing or public repository submission has been established for this study.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe